跳转至内容
Merck
CN

T144

(±)-沙利度胺

≥98%, beta-secretase inhibitor, powder

别名:

(±)-2-(2,6-二氧代-3-哌啶基)-1H-异吲哚-1,3 (2H)-二酮

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C13H10N2O4
化学文摘社编号:
分子量:
258.23
UNSPSC Code:
12352111
eCl@ss:
39180303
PubChem Substance ID:
NACRES:
NA.77
EC Number:
200-031-1
MDL number:
Assay:
≥98%
Form:
powder
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


产品名称

(±)-沙利度胺, ≥98%, powder

ligand

thalidomide

Quality Level

assay

≥98%

form

powder

reaction suitability

reagent type: ligand

color

white

solubility

DMSO: 20 mg/mL, clear

originator

Celgene

SMILES string

O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1

InChI

1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)

InChI key

UEJJHQNACJXSKW-UHFFFAOYSA-N

Gene Information

Application

沙利度胺已被用于阿尔茨海默病 (AD) 小鼠模型的神经病理学研究。该研究报道,长期服用沙利度胺可引起 β-分泌酶抑制,继而减轻类淀粉样病理。此外,沙利度胺也被用于评价其致畸功能。沙利度胺可影响人胚胎干细胞和诱导多能干细胞分化过程中的内胚层分化和神经发育

Biochem/physiol Actions

(±)-沙利度胺选择性抑制肿瘤坏死因子 α 的生物合成(TNF-α)。它还作为血管生成抑制剂、免疫抑制剂、镇静剂和致畸剂发挥作用。此外,已知沙利度胺在难治性多发性骨髓瘤中表现出抗肿瘤功能

Features and Benefits

该化合物由 Celgene 开发。要浏览其他制药公司开发的化合物列表批准的药物/候选药物的列表, 点击这里

Preparation Note

沙利度胺可溶于 DMSO,浓度超过 20 mg/mL。不溶于水和乙醇。


pictograms

Skull and crossbonesHealth hazard

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Acute Tox. 4 Dermal - Repr. 1A

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


商品

Effective in key synthesis reactions like Knoevenagel condensation, thalidomide synthesis, and Suzuki coupling for sustainable chemical transformations.


Marzia Lazzerini et al.
Inflammatory bowel diseases, 21(8), 1739-1749 (2015-07-18)
In a randomized controlled trial, thalidomide has shown to be effective in refractory Crohn's disease in children. This pilot study aimed at evaluating thalidomide in refractory pediatric ulcerative colitis (UC). Double-blind, placebo-controlled randomized clinical trial on thalidomide 1.5 to 2.5
Yoav Mayshar et al.
Journal of cellular and molecular medicine, 15(6), 1393-1401 (2010-06-22)
Teratogens are substances that may cause defects in normal embryonic development while not necessarily being toxic in adults. Identification of possible teratogenic compounds has been historically beset by the species-specific nature of the teratogen response. To examine teratogenic effects on
Tomomi Noguchi et al.
Bioorganic & medicinal chemistry letters, 15(24), 5509-5513 (2005-09-27)
5-Hydroxy-2-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33: 10), which was obtained during our previous structural development studies on thalidomide, was revealed to possess potent anti-angiogenic activity in a human umbilical vein endothelial cell (HUVEC) assay. Thalidomide (1) and its metabolite, 5-hydroxythalidomide (5-HT: 2), which possesses



全球贸易项目编号

货号GTIN
T144-100MG04061837337475
T144-1G04061826739945